Pace seems to be hitting its stride after new management arrived last year with a fresh vision. Having coasted through 2008 up 20%, the firm appears to be on the same track in 2009. Having shed its consumer business, the New Jersey agency is poised to go even deeper into high science. Primovist brings to six the number of oncology-related drugs in Pace's portfolio -- quite a lot for a mid-sized shop. Because of its size, the prevailing economic pressure and the tendency for network consolidation, the 75-person agency faced challenges landing larger accounts.